Lonza Group AG operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Lonza Group AG with three other
pharmaceutical manufacturers in Europe:
H. Lundbeck A/S
sales of 17.04 billion Danish Kroner [US$2.46 billion]
of which 100%
Richter Gedeon Vegyeszeti Gyar Nyilvanosan Mukodo Reszvenytarsasag
(507.79 billion Hungarian Forints [US$1.64 billion]
based in Italy
(1.48 billion Euro [US$1.60 billion]
During the year ended December of 2019, sales at
Lonza Group AG were 5.92 billion Swiss Francs (US$6.02 billion).
increase of 6.8%
versus 2018, when the company's sales were 5.54 billion Swiss Francs.
This was the fifth consecutive year of sales increases at Lonza Group AG
(and since 2014, sales have increased a total of 63%).